Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio

Project description

Enhancing immunotherapy efficacy

Chimeric antigen receptor (CAR) T cells have emerged as powerful weapons against leukaemia and lymphoma. These cells are engineered to recognise specific antigens on cancer cells and kill them. However, the clinical success of this immunotherapy approach has been hampered by antigen heterogeneity, CAR T cell exhaustion and immunosuppression. Funded by the European Innovation Council, the CD20CARNAPT project aims to address these limitations by enhancing the activity of CAR T cells. Researchers will employ the mini-ferritin neutrophil-activating protein of Helicobacter pylori, which can promote cytotoxic T cell responses and revert the immune suppressive profile of macrophages. Through this approach, researchers aim to prime patients’ endogenous immune system against the tumour.

Objective

Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of lymphomas and solid tumours. Elicera’s iTANK platform can circumvent major challenges of CAR-T cells in the treatment of solid tumours, such as antigen heterogenicity, local immunosuppression, and CAR T-cell exhaustion. As such, the iTANK platform has a potential to revolutionise the landscape of the immuno-oncology

Our innovation arms CAR-T cells with NAP from H.pylori which induces a pro-inflammatory microenvironment and activates the patient’s own CD8+ killer T-cells against the whole repertoire of relevant tumour antigen targets. When tumour cells are killed, NAP-activated dendritic cells can take up tumour-associated antigens and prime killer T-cells against these antigens overcoming problems for CAR-T therapy.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

ELICERA THERAPEUTICS AB
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 499 999,00
Address
BOX 5243
402 24 GOTEBORG
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Västsverige Västra Götalands län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 604 499,00
My booklet 0 0